Cargando…
MAb NJ001 inhibits lung adenocarcinoma invasiveness by directly regulating TIMP‐3 promoter activity via FOXP1 binding sites
BACKGROUND: Previously, we developed a monoclonal antibody (mAb) NJ001 that binds to the antigen SP70 in human non‐small cell lung cancer (NSCLC) cells and showed it could inhibit lung adenocarcinoma (AD) growth. Here, we investigated the effect and mechanisms of NJ001 in lung AD metastasis. METHODS...
Autores principales: | Gu, Chunrong, Luo, Ying, Zhang, Shichang, Xu, Jian, Zhang, Jiexin, Ju, Huanyu, Liu, Jingping, Zhang, Lixia, Zhang, Yan, Wu, Lei, Xie, Erfu, Xu, Ting, Pan, Shiyang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471035/ https://www.ncbi.nlm.nih.gov/pubmed/32744429 http://dx.doi.org/10.1111/1759-7714.13593 |
Ejemplares similares
-
SP70-Targeted Imaging for the Early Detection of Lung Adenocarcinoma
por: Xu, Jian, et al.
Publicado: (2020) -
The Study on Newly Developed McAb NJ001 Specific to Non-Small Cell Lung Cancer and Its Biological Characteristics
por: Pan, Shiyang, et al.
Publicado: (2012) -
Serum SP70 is a sensitive predictor of chemotherapy response in patients with advanced nonsmall cell lung cancer
por: Liu, Jingping, et al.
Publicado: (2018) -
The NJ Alliance for Clinical and Translational Science (NJ ACTS) experience: Responding at “warp speed” to COVID-19
por: Thaman, Pragya, et al.
Publicado: (2022) -
Structural characterization of a neutralizing mAb H16.001, a potent candidate for a common potency assay for various HPV16 VLPs
por: Huang, Weijin, et al.
Publicado: (2020)